Kamada (KMDA) Retained Earnings (2012 - 2026)
Kamada (KMDA) posted quarterly Retained Earnings of -$27.4 million for Q1 2026, up 17.85% year-on-year from -$23.2 million in Q1 2025, and down 60.26% on a QoQ basis from -$17.1 million in Q4 2025.
Kamada (KMDA) Retained Earnings (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Retained Earnings for 15 consecutive years, with -$27.4 million the latest figure, recorded in Q1 2026.
- Quarterly Retained Earnings rose 17.85% year-over-year to -$27.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.4 million (up 17.85% YoY) and the FY2025 annual result came in at -$17.1 million, up 33.66% from the prior year.
- Retained Earnings eased to -$27.4 million in Q1 2026 per KMDA's latest filing, from -$17.1 million in the prior quarter.
- Over the last five years, Retained Earnings for KMDA reached as high as -$50293.0 in Q1 2023 and fell as low as -$51.9 million in Q2 2022.
- A 5-year average of -$31.4 million and a median of -$33.3 million in 2025 frame the typical range for Retained Earnings.
- The largest YoY upside for Retained Earnings was 99.9% in 2023 against a maximum downside of 87902.64% in 2023.
- Year by year, Retained Earnings stood at -$48.5 million in 2022, then grew by 17.09% to -$40.2 million in 2023, then surged by 35.98% to -$25.7 million in 2024, then jumped by 33.66% to -$17.1 million in 2025, then slumped by 60.26% to -$27.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$27.4 million, -$17.1 million, and -$20.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | -27.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.36 Mn |
| Dec 31, 2025 | -17.07 Mn |
| Sep 30, 2025 | -20.64 Mn |
| Jun 30, 2025 | -25.93 Mn |
| Mar 31, 2025 | -33.31 Mn |
| Dec 31, 2024 | -25.74 Mn |
| Sep 30, 2024 | -29.55 Mn |
| Jun 30, 2024 | -33.41 Mn |
| Mar 31, 2024 | -37.84 Mn |
| Dec 31, 2023 | -40.20 Mn |
| Sep 30, 2023 | -45.26 Mn |
| Jun 30, 2023 | -48.48 Mn |
| Mar 31, 2023 | -50,293.00 |
| Dec 31, 2022 | -48.48 Mn |
| Sep 30, 2022 | -51,428.00 |
| Jun 30, 2022 | -51.91 Mn |
| Mar 31, 2022 | -47.99 Mn |
| Dec 31, 2021 | -46.16 Mn |
| Sep 30, 2021 | -41.15 Mn |
| Jun 30, 2021 | -40.31 Mn |